Moneycontrol PRO
Upcoming Webinar:Watch a panel of experts discuss: Challenges of continuously evolving regulation for Cryptocurrency, on 7th July at 3pm. Register Now

Buy Indoco Remedies; target of Rs 380: ICICI Direct

ICICI Securities is bullish on Indoco Remedies recommended buy rating on the stock with a target price of Rs 380 in its research report dated December 30, 2020.

December 30, 2020 / 12:42 PM IST
  • bselive
  • nselive
Todays L/H

ICICI Direct's research report on Indoco Remedies

Amid strong recovery in the export business, the company’s overall revenues grew 10.8% to Rs 604 crore. Domestic market growth was subdued amid Covid. EBITDA margins improved 800 bps to 18.1% mainly due to better product mix and lower travel & promotional expenses. Subsequent EBITDA grew 98.7% YoY to Rs 109.7 crore. Net profit for H1 came in at Rs 42.7 crore (up 342% YoY) vs. Rs 9.7 crore in H1FY20.


We maintain BUY rating and arrive at a revised target price of Rs 380 based on ~18x FY23 EPS of Rs 21.


For all recommendations report, click here

Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on are their own, and not that of the website or its management. advises users to check with certified experts before taking any investment decisions.

Broker Research
first published: Dec 30, 2020 12:42 pm
ISO 27001 - BSI Assurance Mark